OR WAIT null SECS
September 22, 2023
Deal to focus on development and commercialization in key emerging countries.
September 21, 2023
Deal aims to provide diabetes treatment to patients across the continent.
September 19, 2023
SaaS’ branded platform expected to help grow manufacturer’s therapeutic development processes.
CDMO will continue to produce commercial antibody cancer drug substance, featuring a new $242 million agreement.
The draft guidance document discusses the development of labeling for proposed biosimilars and interchangeable biosimilars for submission under section 351(k) of the Public Health Service Act.
September 14, 2023
Financial commitment is intended to benefit development and commercialization of new products.
September 13, 2023
Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.
September 12, 2023
How drugmakers can navigate the program’s pricing challenges and regulatory developments.
August 24, 2023
Expansion allows facility to provide E2E services in one location, including commercial manufacturing.
August 10, 2023
The company will occupy approximately 62,000 square feet of the new building.